| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Membrane metallo-endopeptidase-like 1, Membrane metallo-endopeptidase-like 2, NEP2(m), Neprilysin II, NEPII, Neprilysin-2, NEP2, NL2, Membrane metallo-endopeptidase-like 1, soluble form, Neprilysin-2 secreted, NEP2(s), MMEL1, MELL1, MMEL2, NEP2 |
| Entrez GeneID | 79258 |
| WB Predicted band size | 89.4kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This MMEL1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 50-78 amino acids from the N-terminal region of human MMEL1. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于MMEL1(N-term)抗体的3篇参考文献示例(注：文献信息为假设性示例，实际引用需根据真实研究调整)：
---
1. **文献名称**：*MMEL1 metalloprotease expression in Alzheimer’s disease: Role in amyloid-β degradation*
**作者**：Smith J, et al.
**摘要**：本研究通过Western blot和免疫组化，利用N端特异性MMEL1抗体，揭示了MMEL1在阿尔茨海默病患者脑组织中的表达上调，并探讨其通过剪切Aβ肽链发挥潜在神经保护作用的机制。
2. **文献名称**：*Proteolytic processing of MMEL1 in cancer: Insights from N-terminal antibody-based assays*
**作者**：Lee S, et al.
**摘要**：通过针对MMEL1 N端的抗体，作者发现MMEL1在胃癌细胞中可被蛋白酶剪切为活性片段，并证实其通过调控EGFR信号通路促进肿瘤侵袭，为靶向治疗提供新方向。
3. **文献名称**：*Characterization of MMEL1 knockout mice using N-terminal epitope-specific antibodies*
**作者**：Brown K, et al.
**摘要**：研究利用MMEL1 N端抗体验证基因敲除小鼠模型，发现MMEL1缺失导致肠道神经节发育异常，提示其在周围神经系统中的关键功能。
---
如需真实文献，建议通过PubMed或Google Scholar检索关键词“MMEL1 antibody N-terminal”或结合具体研究领域(如神经生物学、癌症)筛选。
MMEL1 (N-term) antibody targets the N-terminal region of Membrane Metalloendopeptidase-Like 1 (MMEL1), a zinc-dependent metalloprotease belonging to the neprilysin (M13) family. MMEL1. also known as NL1 or NEP2. shares structural homology with neprilysin (NEP), an enzyme involved in peptide metabolism, including amyloid-beta degradation in the brain. MMEL1 exists in two splice variants: a transmembrane form (MMEL1-TM) and a soluble secreted form (MMEL1-S), both implicated in neuropeptide processing and extracellular matrix regulation. The N-terminal region is critical for substrate recognition and enzymatic activity.
This antibody is commonly used in research to distinguish MMEL1 from other family members (e.g., NEP) and to study its expression, localization, and function in tissues, particularly in the nervous system. It aids in detecting full-length or truncated isoforms via Western blotting, immunohistochemistry, or immunofluorescence. Studies suggest MMEL1's potential role in neurodegenerative diseases, such as Alzheimer’s, due to its ability to cleave amyloid-beta peptides. However, its exact physiological and pathological mechanisms remain under investigation.
Commercial MMEL1 (N-term) antibodies are typically validated for specificity using knockout controls or siRNA-mediated silencing. Researchers utilize this tool to explore MMEL1's involvement in cellular processes, disease models, and therapeutic targeting strategies.
×
